R. Shames

发表

Effectiveness of a multicomponent self-management program in at-risk, school-aged children with asthma.

T. Robinson, P. Sharek, D. Umetsu, 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Agreement among measures of asthma status: a prospective study of low-income children with moderate to severe asthma.

T. Robinson, P. Sharek, D. Umetsu, 2002, Pediatrics.

Weekly Dosing of Carboplatin Increases Risk of Allergy in Children

P. Fisher, R. Shames, G. Dahl, 2001, Journal of pediatric hematology/oncology.

Gender differences in the development and function of the immune system.

R. Shames, 2002, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Pulmonary Atypical Mycobacterial Infection in a Child with Severe Combined Immune Deficiency

D. Umetsu, R. Shames, M. Cowan, 1999 .

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

A. Gottlieb, H. Nakagawa, K. Papp, 2015, The British journal of dermatology.

On the Fundamental Efficacy of Thyroid-Hormone Therapy in Eating Disorders: Review of Mechanisms and Case Study

R. Shames, Stuart Wenzel, S. Wenzel, 2022, Journal of Restorative Medicine.

Daclizumab improves asthma control in patients with refractory asthma

W. Busse, E. Israel, H. Nelson, 2005 .

Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma

W. Busse, P. Korenblat, R. Shames, 2004 .

Interleukin-4 Inhibition for the Treatment of Asthma

J. Steinke, L. Borish, R. Shames, 2002 .

A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.

C. Cunningham-Rundles, S. Abramson, M. Glovsky, 1999, Clinical immunology.

Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma.

C. Cunningham-Rundles, S. Abramson, E. Stiehm, 1999, Clinical immunology.

Activation of human neutrophil LFA-1 (CD11a) by leukotriene B4

E. Goetzl, R. Shames, 1993, Inflammation.

Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-SN-glycero-3-phosphorylcholine (ET-18-O-OCH3).

R. Shames, F. Valone, N. Ruis, 1994, International journal of immunopharmacology.

Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.

W. Busse, E. Israel, H. Nelson, 2008, American journal of respiratory and critical care medicine.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

T. Waldmann, Darby J. S. Thompson, S. Srivastava, 2003, Journal of autoimmunity.

Inhibition of human HL-60 cell responses to chemotactic factors by antisense messenger RNA depletion of G proteins.

E. Goetzl, P. Albert, R. Shames, 1994, The Journal of biological chemistry.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

S. Targan, G. Van Assche, J. Valentine, 2006, Gut.

PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.

G. D'Haens, W. Sandborn, B. Feagan, 2021, Gastroenterology.

Clinical differences among women with and without self-reported perimenstrual asthma.

S. Janson, D. Heilbron, R. Shames, 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Induction of aggregation of Raji human B-lymphoblastic cells by vasoactive intestinal peptide.

E. Goetzl, A. Robichon, E. Gronroos, 1993, Immunology.